Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Patients With Myelodysplastic Syndrome
NCT00510289Phase 2Terminated
- Sponsor
- Duke University
- Start
- Jul 2006
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Duke University. Started Jul 2006; status: terminated.
02
Drugs
sorafenib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00510289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510289.